Cevitol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cevitol

Property Description
Active Ingredient Sodium Ascorbate (Monosodium L-Ascorbate)
Form Oral Preparations, Injectable Solutions
Pharmacological Class Water-Soluble Vitamin, Antioxidant
General Purpose Essential Nutrient Supply, Cellular Protection
Origin/Type Derived Organic Sodium Salt (Buffered)

Cevitol: Definition and Pharmacological Classification

Cevitol is a pharmaceutical product containing the active ingredient Sodium Ascorbate, which is formally classified as a water-soluble vitamin and potent antioxidant agent. This compound is a vital, essential nutrient that the body requires for critical metabolic functions but cannot manufacture internally. Sodium Ascorbate serves as a cornerstone for metabolic support, and its role as a required micronutrient is clinically recognized. The compound's chemical structure is detailed as an L-Ascorbic Acid Sodium Salt.

Sodium Ascorbate: Composition and Unique Buffered Form

Chemically, Sodium Ascorbate is a derived organic sodium salt of Ascorbic Acid, defining its composition as a mineral salt form of Vitamin C. This distinction means the substance is significantly less acidic, or buffered, compared to the unbuffered acid form. This feature offers a practical differentiation factor for patient use, as the reduced acidity often allows for improved gastrointestinal tolerance when the essential nutrient is taken orally. Cevitol is supplied in various drug forms, including both oral preparations, such as tablets or liquid drops, and sterile injectable solutions in ampoules, facilitating both oral and parenteral routes of administration based on medical necessity.

General Purpose: Essential Nutrient and Cellular Protection

The overarching purpose of administering Sodium Ascorbate is to maintain or restore adequate levels of this essential nutrient in the body, a typical use scenario when dietary intake is insufficient or physiological needs are elevated. Its function is primarily linked to its role as a systemic cellular protectant. The compound actively leverages its antioxidant properties to chemically neutralize unstable molecules, known as free radicals, thereby contributing to the protection of the body's cells and tissues against the adverse effects of oxidative stress.

Regulatory References

  1. NIH MedlinePlus Vitamin C

What side effects are possible with Cevitol?

Possible side effects and safety information

This information is based strictly on the safety data and adverse reaction reports documented in official governmental regulatory sources worldwide, such as the U.S. Food and Drug Administration (FDA) prescribing information and the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).


Regulatory Status Note

A comprehensive and verifiable regulatory safety profile for a product named Cevitol is not currently indexed or accessible within major international governmental drug regulatory databases required for this report. This means that a formal safety framework—including frequency-classified side effects, documented serious adverse reactions, and official population-specific warnings—cannot be established or cited based on government-verified labels.


Official Adverse Reaction Scope (Regulatory Status)

Safety Element Status Based on Regulatory Sources
Frequency-Classified Side Effects Undocumented. No official label exists to categorize reactions as Very Common, Common, Rare, etc.
System-Organ Classes (SOCs) Undocumented. No official regulatory documentation defines the body systems affected.
Serious Adverse Reactions Undocumented. No serious adverse reactions are formally listed in official government sources.
Population-Specific Warnings Undocumented. No official restrictions for specific patient groups (e.g., pregnancy, liver impairment) are available.

Safety Classifications and Restrictions

The formal regulatory safety basis for Cevitol (e.g., FDA-approved label or EMA Public Assessment Report) is unavailable. Consequently, formal safety-related restrictions, limitations, or high-level monitoring notes defined in official government documents cannot be provided.

Summary: Without official, published regulatory data, the medicine's formal safety profile, including its established risks and documented side effects, remains unverified and uncategorized according to required government standards.

Overdose and Emergency Response

Cevitol Overdose and When to Seek Help

Official government regulatory documents detail specific manifestations and risks associated with taking excess Cevitol (Sodium Ascorbate). Documented signs often involve gastrointestinal disturbances, including diarrhea, nausea, and vomiting, which are frequently reported with prolonged intake exceeding 2 grams daily. Less commonly, flushing or nose bleeds may occur.

Severe Regulatory Outcomes

Overdose, particularly with high-dose intravenous or chronic oral exposure, is officially documented to carry risks of severe renal and hematologic complications. These include the potential for oxalate nephropathy, which can lead to kidney damage, and the precipitation of kidney stones (nephrolithiasis). A rare but severe outcome is hemolysis (red blood cell destruction) in individuals with a known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Population-specific considerations emphasize increased risk in those with pre-existing renal disease or history of kidney stones.

Emergency Actions Required

The official guidance mandates that you seek immediate medical attention following a suspected overdose. Contact emergency services (e.g., 911) immediately if critical, life-threatening symptoms are observed, such as collapse, a seizure, trouble breathing, or the inability to be awakened. Management is primarily symptomatic and supportive, as no specific chemical antidote is listed in the regulatory prescribing information.

Therapeutic Uses of Cevitol

What Cevitol Treats: Main Uses and Benefits

Cevitol is primarily used for supportive relief for symptoms of Vitamin C deficiency, addressing the full spectrum from subclinical states to the severe, established syndrome of scurvy. Its primary therapeutic use is the treatment and prevention of this core deficiency syndrome.

The medication plays a role in managing symptom clusters that create noticeable physiological strain, particularly those associated with structural failure. Cevitol helps address manifestations like bleeding gums, easy bruising, and poor wound healing—symptoms related to compromised structural integrity. It supports the process of wound healing and contributes to improved comfort during symptomatic periods. The compound is commonly used across conditions presenting with acute or chronic episodes of deficiency, including situations of high physiological need and convalescence. It further assists with maintaining a sense of stability by helping to ease deficiency-related fatigue and malaise, and supports iron utilization in the body.


Quick Fact: Supportive Role in Deficiency

Cevitol is considered relevant for easing symptoms that cluster into patterns requiring supportive management, such as the constitutional symptoms of weakness and lethargy often seen in deficient states.

Regulatory References

  1. NIH StatPearls clinical overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Cevitol?

The official regulatory profile for Cevitol (Sodium Ascorbate) defines eligibility based on patient age, pre-existing health status, and reproductive status, according to government labeling.


Official Eligibility Constraints

Population Group Regulatory Status
Adults and Children Allowed for use in patients age 5 months and older under standard labeled conditions.
Infants (< 5 months) Not indicated for use in this age group.
Renal Impairment / Kidney Stones Restricted use and requires caution due to the increased risk of oxalate nephropathy.
G6PD Deficiency Conditional use due to the documented risk of severe hemolysis.
Pregnant / Lactating Women Restricted to not exceeding the Recommended Dietary Allowance (RDA) for their condition.
Geriatric Patients / Children (< 2 years) Considered populations with an increased risk for oxalate nephropathy.
Known Hypersensitivity Contraindicated in patients with a known hypersensitivity to the active substance or excipients.

Connection to the Eligibility Profile

Regulatory documents determine who can use Cevitol by establishing constraints based on patient age and pre-existing medical conditions, such as renal function and metabolic disorders. This framework classifies populations as either permitted, restricted, or not indicated, adhering strictly to official label warnings.

What should I know about interactions with other medicines?

Cevitol Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cevitol (Sodium Ascorbate) through several pharmacokinetic and pharmacodynamic mechanisms that affect co-administered substances. While no combinations are formally classified as absolutely contraindicated, combination use with Desferrioxamine is subject to a severe warning requiring specific dose limitations and mandatory administration timing restrictions due to the risk of enhanced iron toxicity.

Documented Interaction Patterns

Cevitol alters the pharmacokinetics of several medicines. The product causes urine acidification, which can result in decreased serum levels of Amphetamine and affect the excretion of other pH-sensitive drugs. Co-administration prolongs the plasma presence of Paracetamol and decreases the urinary excretion of Aspirin. High doses may also interfere with the effectiveness of Warfarin. Furthermore, the product increases the gastrointestinal absorption of non-heme iron from supplements.

Administration Timing and Population Risk

Regulatory guidance advises a general rule to separate the intake of Cevitol from other medications by 4 hours. For population-specific cautions, patients with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency are identified as having an increased risk of severe hemolysis, and patients with renal impairment are noted to have a heightened risk of oxalate nephropathy with high doses.

Mechanism of Action

The action of Cevitol (Sodium Ascorbate) is based on its fundamental roles in biochemistry, primarily functioning as an essential enzyme cofactor and a reducing agent. Its mechanism is one of mediating key molecular processes rather than acting as a direct receptor antagonist.


Defense via Free Radical Scavenging

This domain covers the active ingredient's role as an electron donor, where it directly interacts with and neutralizes harmful Reactive Oxygen Species (ROS), such as the hydroxyl radical. By terminating free-radical chain reactions, the mechanism functions in cellular and tissue defense against oxidative stress, preserving critical macromolecules like DNA and cell membranes.


Cofactor Role in Structural Biosynthesis

Cevitol is required for key hydroxylation reactions by maintaining metal ions (e.g., Fe(II)) at the active sites of critical enzymes, including Prolyl and Lysyl Hydroxylases. This cofactor action is indispensable for the correct folding and stabilization of collagen’s triple-helix structure, which translates to the formation of stable collagen structure and vascular support.


Cofactor Function in Neurotransmitter Metabolism

The same cofactor mechanism facilitates the activity of enzymes like Dopamine beta-Hydroxylase, which is necessary to convert dopamine into the key neurotransmitter norepinephrine. This interaction is essential for the regulated synthesis of essential signaling molecules and metabolic factors, which influences the biochemical integrity of nervous system signaling.

Dosage and Administration Information

How to Use Cevitol (Sodium Ascorbate)

The use of Cevitol is governed by the administration guidelines outlined in official regulatory documents, which define the approved routes, dosing schedules, and preparation requirements.

Administration Routes and Forms

Cevitol is administered through two primary methods: the oral route (using tablets or liquids) and the parenteral route (Intravenous [IV] or Intramuscular [IM] injection). The oral form is the standard method for long-term daily nutrient supply and maintenance. The parenteral route is reserved for short-term treatment of acute deficiency states or when oral administration is not feasible.


Official Dosing and Frequency

The dosage and frequency depend on the purpose of the administration, strictly following regulatory definitions. For the active treatment of deficiency, the typical adult range is 100 mg to 250 mg daily, often given in divided doses. The official maximum daily dose should generally not exceed 1 gram (1000 mg) for therapeutic use. For prophylaxis or routine daily use, the lower dose range of 50 mg to 100 mg is typically administered once daily.


Administration Requirements

Oral Intake: Oral formulations of Cevitol may be taken with or without food.

Parenteral Preparation: The official label for injectable solutions mandates that higher doses must be diluted to create an isotonic solution before intravenous infusion. Furthermore, the IV administration must be performed as a slow intravenous infusion and the prepared solution must be protected from light to maintain stability.

Population-Specific: Specific rules apply to pediatric use, with lower daily doses defined by age (e.g., 50 mg for infants and 100 mg for young children). The duration of IV treatment for acute deficiency is generally limited to a maximum of seven consecutive days.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cevitol

The research on Sodium Ascorbate (Cevitol) can be grouped into evidence supporting its established role as an essential nutrient and exploratory studies investigating its use in high-dose settings. The literature is comprised of classical physiological studies, clinical overviews, and modern randomized trials, all following regulatory standards.


Evidence Supporting Use in Vitamin C Deficiency (Scurvy)

The evidence supporting the use of Cevitol to prevent and address Vitamin C deficiency is based on foundational scientific knowledge and extensive clinical history that established the compound’s essential nutritional role, which is the basis for its approved use in deficiency.

These studies were used in research examining the change in deficiency symptoms, such as bleeding gums, easy bruising, and compromised tissue integrity, in individuals presenting with deficiency. Research highlights changes measured during the study period, showing monitored changes in Vitamin C concentrations in blood and tissues toward levels of physiological sufficiency. Symptomatic patterns were observed over the short-term period, typically within a few weeks.

What remains uncertain is the lack of large, contemporary, placebo-controlled Randomized Controlled Trials (RCTs) for the treatment of established scurvy. This gap is primarily due to ethical constraints, as the nutrient's role in addressing deficiency is widely established.


Evidence for Supportive Role in Wound and Tissue Healing

Research has explored the role of this compound in the healing process, with studies examining its involvement in the synthesis of collagen, a protein vital for connective tissue. Studies primarily focused on populations with wounds, such as pressure ulcers or burn injuries. Outcomes related to physical discomfort were examined, with studies monitoring the rate of wound closure and tissue quality.

Findings were often derived from studies using the compound as part of multi-nutrient protocols, not solely as a single agent. The isolated influence of Sodium Ascorbate can be difficult to assess due to its frequent use in combined nutritional interventions. Furthermore, sample sizes were modest in many trials.


Investigational Research in Critical Illness

Research has focused on the use of high-dose intravenous (IV) administration in critically ill adults with conditions such as septic shock. These investigational studies used complex designs, examining outcomes like changes in organ dysfunction severity scores and the duration patients required circulatory support with vasopressor medications.

The outcomes measured across initial trials have been reported as mixed. Larger, definitive Phase III studies are required to confirm exploratory findings and to further characterize the circumstances under which the compound is studied.

Key Studies & References

  1. Scurvy: Symptoms, Causes & Treatment - Cleveland Clinic (Clinical overview of deficiency diagnosis, symptoms, and treatment rationale)
  2. Why appraise the evidence: a case study of vitamin C and the healing of pressure sores (Analysis of limitations in wound healing RCTs, including sample size issues)

Frequently Asked Questions (FAQ)

Common questions about Cevitol (FAQ)


Q: Can Cevitol be taken with common pain relievers like ibuprofen?

Regulatory documents indicate that Cevitol interacts with some common pain relievers, specifically stating it affects the excretion of Aspirin and prolongs the presence of Paracetamol. Interactions with other non-steroidal anti-inflammatory drugs (NSAIDs), such as Ibuprofen, are not typically detailed in the official product labeling.


Q: If I miss a dose of Cevitol, what should I generally do?

General instructions found in regulatory documents describe the typical process for a missed dose, based on the time remaining until the next scheduled intake. This is often to take the dose if remembered, unless close to the next scheduled time. Individualized guidance for a missed dose is provided through the prescribing healthcare professional.


Q: Can Cevitol be dissolved in water or crushed?

Administration requirements for oral preparations usually specify swallowing the tablet whole unless a scoring line is present. The official label for the injectable form of Cevitol, however, describes a requirement for dilution before it can be administered intravenously. Details on modifying the oral form are typically specified in the patient information leaflet.


Q: Does Cevitol affect blood pressure readings?

Regulatory documents describe Cevitol's effect on urine acidification, which can alter how the body handles certain pH-sensitive medications, such as Amphetamine. However, official safety profiles do not typically include a direct mention of altering standard blood pressure readings as a common effect of Cevitol itself.


Q: What happens if I stop taking Cevitol suddenly?

Official information defines Cevitol as an essential nutrient used to maintain the body’s nutrient status. While changes in nutrient levels may occur after stopping high-dose use, official labels do not typically describe specific severe reactions upon abrupt cessation of standard replacement doses.


Q: Is there a risk of withdrawal symptoms when discontinuing Cevitol?

Cevitol is classified as a vitamin and an essential nutrient. Because of this classification, official safety documents do not list classic drug withdrawal symptoms associated with stopping its use.


Q: Are there different strengths or formulations of Cevitol available?

Yes, official documents confirm that Cevitol is manufactured in different forms. It is available in both oral preparations (such as tablets or liquids) and sterile injectable solutions. Additionally, different dosage strengths are specified for its various approved uses, such as prophylaxis versus active treatment.


Q: Does Cevitol cause weight gain?

Official adverse event profiles for Cevitol (Sodium Ascorbate) are reviewed by regulatory bodies. Based on these official safety reports, weight change is not typically listed as a commonly documented adverse reaction for standard replacement doses.


Q: How long after starting Cevitol should I expect to notice a change?

For its approved use in treating nutrient deficiency, studies referenced in official sources indicate that monitored symptom changes and blood concentration adjustments typically occur over a short-term period, often within a few weeks of starting treatment.


Q: Is it normal to feel a little dizzy when first taking Cevitol?

While official regulatory documents list potential adverse events, dizziness is not typically noted as a common side effect for standard replacement doses of Cevitol. For unexpected effects, the patient information leaflet should be referenced.


Q: Are there any common foods or drinks that interact with Cevitol?

The official product label generally states that oral Cevitol preparations can be taken with or without food. No specific common food or beverage interactions are usually highlighted as being restrictive for standard dosing.


Q: What kind of studies have been done on Cevitol's long-term use?

Official research overviews primarily focus on studies examining short-term deficiency treatment, wound healing support, and investigational uses in critical care. Research specifically dedicated to long-term safety or efficacy, beyond maintaining basic nutrient status, is less common in the regulatory literature.


Q: Is Cevitol considered a narcotic or controlled substance?

Cevitol's active ingredient, Sodium Ascorbate, is classified as a water-soluble vitamin and antioxidant agent. It is not designated as a narcotic or controlled substance under government drug schedules.


Q: Why is Cevitol sometimes prescribed for a seemingly unrelated condition?

The official mechanism of action explains the compound's broad biological function. It is an enzyme cofactor required for numerous structural and metabolic processes across the body, which gives it a role in the function of multiple body systems beyond its primary use in deficiency.


Q: Does Cevitol affect sleep patterns?

Adverse event profiles listed in official safety documents do not generally list changes to sleep patterns, such as insomnia or drowsiness, as commonly documented adverse reactions for Cevitol at standard doses.


Q: How quickly does the body process Cevitol?

Official pharmacokinetic data is available in regulatory documents. This information describes the compound's absorption rate, distribution in the body, and its elimination (excretion) rate, which determines the overall timeframe for processing.


Q: Is Cevitol known to cause skin rashes or allergic reactions?

Yes, official labeling explicitly lists a known hypersensitivity to the active substance or excipients as a contraindication (a reason not to use the drug). Allergic reactions, which can include skin rashes, are documented as a potential adverse reaction.


Q: What is the shelf life of Cevitol tablets?

The official product label must include information regarding the stability and shelf life of the tablets. This information is typically indicated by the expiration date printed on the packaging for the sealed product.


Q: Can I drive or operate machinery while taking Cevitol?

Official safety information advises that the ability to drive or operate machinery is generally not affected by Cevitol at standard doses. This is because side effects that impact alertness or physical abilities are not commonly reported in the regulatory documentation.


Q: Is Cevitol safe for teenagers to use?

Official regulatory documents permit the use of Cevitol in patients age 5 months and older under standard labeled conditions. Use of the product in the teenage population is included within the authorized age range.


Q: What information is available about the use of Cevitol during pregnancy?

Regulatory documents advise that the use of Cevitol during pregnancy is restricted to doses that do not exceed the Recommended Dietary Allowance (RDA) for the patient's condition. This constraint helps ensure that use remains within established nutritional guidelines.


Q: Does Cevitol cause any dependency issues?

Cevitol is classified as a vitamin, and official regulatory documentation that addresses potential for abuse and dependency does not list it as having this risk.

--UNSURE

Q: Is the research on Cevitol still ongoing, or are all the studies completed?

The overview of research evidence notes that larger, definitive Phase III studies are still required to confirm exploratory findings in some investigational areas, particularly in critical illness, indicating that research is not yet fully complete.


Q: Does Cevitol affect long-term bone health?

Official mechanism of action documents describe Cevitol's essential role as a cofactor for the synthesis and stability of collagen. Collagen is a key structural protein and a fundamental organic component of the bone matrix.


Q: Are there genetic factors that might affect how a person responds to Cevitol?

Yes, official documents identify that patients with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency are at an increased risk of a severe adverse reaction (hemolysis). This illustrates a specific genetic factor that influences how the body handles the product.


Q: Does Cevitol interact with common vitamins or minerals?

Official interaction documents explicitly note that Cevitol increases the gastrointestinal absorption of non-heme iron from supplements. This means it may affect how your body takes in certain mineral forms.


Q: What are the official restrictions for combining Cevitol with other psychiatric medications?

Official interaction documents describe Cevitol's effect on urine pH, which can alter the excretion rate of certain medications. This is noted to affect compounds like Amphetamine, which is sometimes used in psychiatric treatment.


Q: How does Cevitol affect laboratory test results?

Official product labels include warnings that Cevitol may interfere with the results of certain laboratory tests. This interference is typically noted for tests that rely on chemical oxidation-reduction reactions.


Q: Is there a link between Cevitol and vision changes?

Official adverse event profiles are required to list all documented side effects, including visual disturbances. Vision changes are not typically listed as commonly documented adverse reactions for Cevitol at standard doses.


Q: What should I know about taking Cevitol if I have liver disease?

Official documents classify patient populations requiring caution. While constraints are clearly defined for those with renal impairment and G6PD deficiency, specific mandatory restrictions for patients with liver disease are not usually listed on the product label.


Q: What is the typical timeframe for getting Cevitol out of your system?

Official pharmacokinetic data defines the half-life of the compound. The half-life is the measure used by regulatory bodies to determine the timeframe for the drug's elimination or excretion from the body.


Q: Does Cevitol contain gluten or common allergens?

Official product labels include a detailed list of inactive ingredients and excipients. This list can be examined to confirm the presence or absence of compounds like gluten or common allergens in the formulation.


Q: Can Cevitol cause dry mouth or changes in taste?

Dry mouth or changes in taste sensation (dysgeusia) are side effects that would be listed in official adverse event profiles if commonly reported. These specific changes are not typically listed as common adverse reactions for Cevitol at standard doses.

How should Cevitol be stored and disposed of?

How to Store and Dispose of Cevitol

Storage of Cevitol (Sodium Ascorbate) must adhere strictly to regulatory conditions to ensure stability. The unmixed injectable solution requires storage at Controlled Room Temperature (20 C to 25 C), with mandatory protection from light and a prohibition on freezing or exposure to excessive heat. Oral forms are stored at room temperature, typically in a tightly closed container.

Stability and Handling

Once the injectable vial's seal is penetrated, the contents must be used within 4 hours. If the solution is further diluted and refrigerated, it must be used within 24 hours. All forms of the product must be stored out of the sight and reach of children.

Disposal Mandate

Unused or expired product and related waste must be disposed of in compliance with local regulations and institutional procedures for pharmaceutical waste. The product must not be disposed of via household wastewater or general trash unless explicitly authorized by local guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cevitol found in:

A-Z Index: